Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients (ABSOLUTE)
A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH
Sponsor: Astellas Pharma Korea, Inc.
Listed as NCT01736033, this PHASE4 trial focuses on Benign Prostate Hyperplasia and remains ongoing. Sponsored by Astellas Pharma Korea, Inc., it has been updated 8 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Unknown PHASE4
-
Sep 2025 — Present [monthly]
Unknown PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
-
Jul 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Korea, Inc.
- Medical Research Collaborating Center, Seoul, Korea
- Seoul National University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .